Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
https://european-biotechnology.com/wp-content/uploads/2024/04/Eppendorf_BioFlo120.jpg360640Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-11-16 00:00:002024-04-02 15:51:38Eppendorf BioFlo® 120 Bioprocess Control Station
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
https://european-biotechnology.com/wp-content/uploads/2024/04/BI_oncology.jpg673712Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-11-15 14:54:302018-11-15 14:54:30Boehringer and Epizyme enter US$300m deal
https://european-biotechnology.com/wp-content/uploads/2024/04/RLS_123rf__Sorapop_Udomsri_93295502_s.jpg565847Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-11-15 05:28:002018-11-15 05:28:00Breakthrough in restless legs syndrome
https://european-biotechnology.com/wp-content/uploads/2024/04/KarlKeegan_web_bw.jpg225225h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-11-14 16:25:002018-11-14 16:25:00Hox Therapeutics appoints Karl Keegan as CEO
AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
https://european-biotechnology.com/wp-content/uploads/2024/04/RSV_SOBI_AZ.jpg19051772Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-11-14 07:01:002018-11-14 07:01:00SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
https://european-biotechnology.com/wp-content/uploads/2024/04/CDC_Neisseria-scaled.jpg25601978Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-11-12 07:05:232018-11-12 07:05:23Antibiotic resistance spreading across Europe
Forbion leads €40m financing in Inflazome Ltd
Latest NewsInflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
EC advisors call for update of GM legislation
Latest NewsThe EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.
Eppendorf BioFlo® 120 Bioprocess Control Station
ProductsThe flexible BioFlo 120 bioreactor/fermentor control station is capable of microbial fermentation as well as mammalian cell culture applications.
Boehringer and Epizyme enter US$300m deal
Latest NewsBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
Latest NewsResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
Hox Therapeutics appoints Karl Keegan as CEO
AppointmentsHox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
Latest NewsAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Amal bags €21.2m financing
Latest NewsSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.
Antibiotic resistance spreading across Europe
Latest NewsAntimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
Latest NewsA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).